RxSight (RXST) Enterprise Value (2020 - 2026)

RxSight's Enterprise Value history runs 7 years deep, the most recent figure standing at -$418.2 million for Q1 2026.

• Quarterly Enterprise Value rose 2.89% year-over-year to -$418.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$418.2 million (up 2.89% YoY) and the FY2025 annual result came in at -$436.3 million, down 83.91% from the prior year.
• Enterprise Value was -$418.2 million for Q1 2026 at RxSight, up from -$436.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$143.8 million in Q1 2022 and bottomed at -$442.0 million in Q2 2024.
• A 5-year average of -$300.9 million and a median of -$253.9 million in 2023 frame the typical range for Enterprise Value.
• Peak annual rise in Enterprise Value reached 32.11% in 2022, while the deepest fall reached 185.13% in 2022.
• RxSight's Enterprise Value stood at -$199.8 million in 2022, then slipped by 22.49% to -$244.7 million in 2023, then increased by 3.05% to -$237.2 million in 2024, then sank by 83.91% to -$436.3 million in 2025, then grew by 4.14% to -$418.2 million in 2026.
• Business Quant data shows RXST's Enterprise Value at -$418.2 million in Q1 2026, -$436.3 million in Q4 2025, and -$425.4 million in Q3 2025.